These results provided a convincing evidence that GM-CSF therapy might be a promising therapeutic option in treating aPAP, furthermore, inhaled GM-CSF would have more benefits on aPAP patients than subcutaneous route. This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.